The preclinical pharmacological profile of WAY-132983, a potent M1 preferring agonist.

  title={The preclinical pharmacological profile of WAY-132983, a potent M1 preferring agonist.},
  author={A C Bartolomeo and Hugh Morris and Jerry J. Buccafusco and Nancy J Kille and Sharon J Rosenzweig-Lipson and M G Husbands and Annmarie L. Sabb and Magid A Abou-Gharbia and John A. Moyer and C A Boast},
  journal={The Journal of pharmacology and experimental therapeutics},
  volume={292 2},
Muscarinic M1 preferring agonists may improve cognitive deficits associated with Alzheimer's disease. Side effect assessment of the M1 preferring agonist WAY-132983 showed significant salivation (10 mg/kg i.p. or p.o.) and produced dose-dependent hypothermia after i. p. or p.o. administration. WAY-132983 significantly reduced scopolamine (0.3 mg/kg i.p.)-induced hyperswimming in mice. Cognitive assessment in rats used pretrained animals in a forced choice, 1-h delayed nonmatch-to-sample radial… CONTINUE READING
17 Citations
38 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 17 extracted citations


Publications referenced by this paper.
Showing 1-10 of 38 references

Effects of muscarinic cholinergic agents on spontaneous swimming in rats

  • JP Symons, M Smith, JG Marriott, RE Davis
  • Soc Neurosci Abstr
  • 1986
Highly Influential
4 Excerpts

Age-related differences in distractibility and response to methylphenidate in monkeys

  • MA Prendergast, WJ Jackson, +4 authors JJ Buccafusco
  • Cerebral Cortex
  • 1998
1 Excerpt

Focus on donepezil: A reversible acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease

  • JP Rho, LG Lipson
  • Hosp Form 32:677–684
  • 1997
2 Excerpts

Similar Papers

Loading similar papers…